Company intelligence / Profile preview

Navire Bio

United States

Ownership: Private
Development stage: Other

Overview

BBP-398, a SHP2 inhibitor acting as a molecular glue, is being evaluated in multiple clinical studies for solid tumors driven by MAPK pathway mutations, including RAS and RTK mutations.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Bristol Myers Squibb (exclusive license for BBP-398 in oncology outside Asia)LianBio (strategic collaboration for Asia)Amgen (clinical collaboration for BBP-398 + sotorasib)The University of Texas MD Anderson Cancer Center

Beyond the preview

Go deeper on Navire Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navire Bio.

Explore the full profile